Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YLY LiYHYongxian Hu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows baseline PET-CT predicts cytokine release syndrome and progression-free survival in R/R MM patients undergoing CAR T-cell therapy.

Key Points

  • Severe cytokine release syndrome is linked to baseline PET-CT metrics in CAR T-cell therapy.
  • High metabolic tumor volume and total lesion glycolysis are adverse prognostic indicators for survival.
  • Analysis involved 62 patients with relapsed/refractory multiple myeloma receiving CAR T-cell therapy.
  • Findings could inform treatment strategies to manage risks in patients with relapsed multiple myeloma.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d687https://doi.org/10.1182/blood-2025-5855
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025
  2. 2PET/CT parameters as predictors of early progression risk in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation2025
  3. 3Predicting survival outcomes in CAR-t treated B-cell lymphoma by combining PET/CT imagingand clinical features2025
  4. 4Semantic features associated with outcome in patients treated with CAR-T therapy2025
  5. 5Predictive Power of Baseline [18F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell Therapy2025